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ABSTRACT
The detection of functional growth factor (GF)
receptors on subpopulations of hemopoietic cells may
provide a further dissection of immature cell subsets.
Since little information is available about coexpression
of different GF receptors at the level of single hemopoi-
etic cells, we studied the feasibility of simultaneous cell
staining with a combination of biotin- and digoxigenin-
labeled GFs for flow cytometric detection of functional
receptors. Using this methodology, coexpression of Kit
and receptors for erythropoietin (EPO), interleukin 6
(IL-6), and GM-CSF on hemopoietic cells was studied
by triple-staining of rhesus monkey bone marrow (BM)
cells with labeled GFs and antibodies against other cell
surface markers. Most of the immature, CD34++ cells
were Kit+ but did not display detectable levels of EPO-
receptors (EPO-Rs) or GM-CSF-R. Approximately
60% of these CD34++/Kit+ cells coexpressed the IL-6-R,
demonstrating that immature cells are heterogeneous
with respect to IL-6-R expression. Maturation of mono-
myeloid progenitors, as demonstrated by decreasing
CD34 and increasing CD11b expression, is accompanied
by a decline of Kit and an increase in GM-CSF-R
expression in such a way that Kit+/GM-CSF-R+ cells are
hardly detectable. IL-6-R expression is maintained or
even increased during monomyeloid differentiation.
IL-6-R and GM-CSF-R were not identified on most
CD71++ cells, which indicated that these receptors are
probably not expressed during erythroid differentiation.
Together with previous results, our data show that both
Kit and CD71 are upregulated with erythroid commit-
ment of immature progenitors. Upon further differenti-
ation, Kit+/EPO-R– cells lose CD34 and acquire EPO-R.
Maturing erythroid cells eventually lose CD71 and Kit
expression but retain the EPO-R. In conclusion, this
approach enables further characterization of the speci-
ficity of GFs for different bone marrow subpopulations.
Apart from insight into the differentiation stages on
which individual GFs may act, information about recep-
tor coexpression may be used to identify individual cells
that can respond to multiple GFs, and allows for further
characterization of the regulation of lineage-specific 
differentiation. Stem Cells 1997;15:275-285
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INTRODUCTION
Survival, growth, and differentiation of hemopoietic cells
depend on binding of growth factors (GFs) to specific cell sur-
face receptors. Studies with monoclonal antibodies (mAbs)
against GF receptors (GF-Rs) or with labeled GF molecules
have enabled analysis of the distribution of GF-Rs on hemo-
poietic cells by means of multiparameter flow cytometry [1].
Such approaches enable analysis of receptor expression in
relation to the presence of other cell-surface antigens.
To detect receptor-expressing cells, the use of labeled
GFs is preferable to that of antireceptor mAbs, because mAbs
recognize only one epitope of a receptor, whereas high-
affinity GF-Rs for many of the GFs active in hemopoiesis
are complexes of more than one subunit [2-4]. Moreover,
some of these subunits can be shared by receptors for dif-
ferent GFs [5-9]. Therefore, detection of receptor-express-
ing cells based on binding of the physiological ligand itself
is more indicative of the presence of functional receptors
than of the binding of antibodies.
Previously, we have used biotin-labeled GFs to study
expression of one GF-R in relation to other parameters, such
as the presence of markers for early hemopoietic cells, in
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particular CD34 [10, 11] and markers that identify activated
or differentiating cells, (e.g., CD11b for monocytes and gran-
ulocytes, and CD71 for erythroid cells [12, 13]). This approach
has provided information on the expression of receptors for
interleukin 3 (IL-3), IL-6, GM-CSF, stem cell factor (SCF),
and erythropoietin (EPO) on normal hemopoietic cells, and
allowed us to compare the receptor phenotype of immature
normal cells with that of their malignant counterparts in
patients with chronic myeloid leukemia [14-19].
The possibility to simultaneously detect two or more
GF-Rs on the same cells could help explain functional and
physiological interactions between these GFs on hemopoi-
etic cells. This would also be helpful to further delineate dif-
ferential expression of these GF-Rs during differentiation of
stem cells into mature cells of distinct lineages.
As an alternative to biotinylation, GFs can be labeled with
the 391 D molecule digoxigenin (DIG) [20, 21], which can be
detected using anti-DIG antibodies. This approach has
recently been used to identify binding and internalization of
DIG-labeled basic fibroblast GF by target cells [21]. In the
present study, we have examined the feasibility of directly
studying the coexpression of two GF-Rs on hemopoietic cell
subsets by staining rhesus monkey bone marrow (BM) cells
with combinations of biotin- and DIG-labeled GFs. By com-
bining these labeled GF molecules with mAbs against CD34,
CD11b, and CD71, we have examined receptor coexpression
patterns during development of stem cells to mature blood
cells of myelomonocytic and erythroid lineages to demon-
strate that such an approach is feasible and yields results that
are consistent with existing functional data. For these studies,
we used rhesus monkey BM cells, since extensive data on
single receptor staining were already available [15-18].
MATERIALS AND METHODS
Labeling of GFs with DIG or Biotin
Recombinant human SCF (a gift of Dr. S. Gillis of Immunex,
Seattle, WA) [22] was labeled with DIG using Digoxigenin-3-O-
methylcarbonyl-e -aminocaproic acid-N-hydroxy-succinimide
ester (NHS-DIG, Boehringer Mannheim; Mannheim, Germany)
under conditions similar to those described previously for
SCF labeling with biotin-N-hydroxy-succinimide ester
(NHS-Biotin) [17]. Briefly, NHS-DIG dissolved in dimethyl-
sulfoxide was added to 5 µg aliquots of SCF in 0.05 M
phosphate-buffered saline, pH 8.5, containing 0.02% (vol/vol)
Tween-20, at molar DIG:Protein (D:P) ratios of 10:1, 50:1,
or 100:1. A control sample was incubated with dimethyl-
sulfoxide without DIG (D:P 0). After 3 h incubation at
room temperature in the dark, DIG-SCF molecules were
separated from the remaining free DIG molecules in the
samples by size exclusion chromatography on a 1 ml Sephadex
G-25 column (Pharmacia; Uppsala, Sweden), equilibrated in
phosphate-buffered saline, pH 7.4, containing 0.02%
(wt/vol) Tween-20.
Human glycosylated recombinant IL-6 (kindly provided
by Ares-Serono; Geneva, Switzerland) and human recombi-
nant GM-CSF (a gift from Genetics Institute; Cambridge MA)
were biotinylated using biotin-N-hydroxy-succinimide ester
(Sigma; St. Louis, MO) under conditions similar to the
NHS-DIG labeling of SCF as described previously [15, 16].
Human recombinant EPO (supplied by Behringwerke
Aktiengesellschaft; Marburg, Germany) was biotinylated
using biotin-aminocaproyl-hydrazide (Calbiochem; La Jolla,
CA) as described previously [23].
Labeled GFs were stored at -80°C in the presence of
0.02% (wt/vol) sodium azide.
Cell Lines and Biological Activity Assay
Before adding sodium azide, the ability of the labeled
GF preparations to stimulate cell proliferation was assayed
using the appropriate GF-dependent cell lines, as described
[15-17]. Briefly, the proliferative response of the human fac-
tor-dependent cell line MO7e was used to determine the
activity of SCF or GM-CSF [24, 25], the human multifactor-
responsive myeloid cell line TF-1 was used for EPO [26],
and the IL-6-dependent murine plasmacytoma cell line
T1165 for IL-6 [27]. Cells (1-5 · 104 per well of 96-well
flat-bottom microtiter plates) were cultured in 200 µl culture
medium containing serial dilutions of GF. After 48 h, 0.25
µCi 3H-Thymidine was added to each well. The cells were
harvested after 16-18 h of thymidine incorporation, and the
radioactivity was measured in a liquid scintillation counter.
Alternatively, to determine the viable cell content of each
well, a commercial proliferation kit (CellTiter 96 AQueous
nonradioactive cell proliferation assay; Promega; Madison,
WI) was used, based on the colorimetric assay described by
Mosmann [28]. Therefore, the cells were cultured for three
days, after which a mixture of 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetra-
zolium (MTS) and phenazine methosulfate was added to the
wells according to the manufacturer’s instructions. After 
4-18 h, the quantity of formazan formed by conversion of MTS
by dehydrogenase enzymes in metabolically active cells was
measured as the amount of 450 nm absorbance in a Bio-Rad
model 450 microplate reader (Bio-Rad; Hercules, CA).
Low-Density BM Cell Preparation
Young adult rhesus monkeys (Macaca mulatta) from
the TNO Primate Center, Rijswijk, The Netherlands, were
used as BM donors. BM was collected by piercing the head
of the humeral shaft with a pediatric spinal needle, or by
extrusion of the cells in a tissue press from the cleansed
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bones of a monkey that was sacrificed for collection of BM for
various experiments and transplantation purposes [29]. All
animal experiments were performed in accordance with
national ethical regulations. BM was collected in Hank’s
Hepes buffered salt solution (HH) with heparin and DNAse
(0.5 mg/ml). A buffy coat fraction was obtained by centrifug-
ing the cells for 15 min at 2,500 rpm at room temperature. To
enrich for progenitor cells, buffy coat cells were subjected to
centrifugation for 30 min at 2,000 rpm at room temperature
over a discontinuous bovine serum albumin density gradient
[30] consisting of 25%, 23%, 22%, 21%, and 17% (wt/vol)
bovine serum albumin in 0.2 M Tris-buffer/phosphate buffer,
pH 7.2. Fractions were collected and washed in HH. Erythro-
cytes were lysed using 10 mM potassium bicarbonate, 155
mM ammonium chloride, pH 7.4, containing 0.1 mM EDTA.
Immunocytochemical Staining
Cells were incubated overnight on ice with DIG-SCF
and either biotin-EPO, biotin-IL-6, or biotin-GM-CSF in
HH, containing 2% (vol/vol) fetal calf serum (FCS), 0.05%
(wt/vol) sodium azide, and DNAse (0.5 mg/ml). Specificity
of binding of the labeled GF samples was determined by
incubating the cells in the presence of a 100-fold molar
excess of unlabeled GF. After each incubation the samples
were washed in HH with FCS and azide. The cells were
stained for 30 min on ice with mouse anti-DIG antibodies
(Boehringer Mannheim), followed by a mixture of fluores-
cein isothiocyanate- (Dako A/S; Glostrup, Denmark) or phy-
coerythrin (PE)-labeled goat antimouse antibodies (Sigma)
and PE- (Molecular Probes; Eugene, OR) or TriColor-
labeled streptavidin (Caltag; San Francisco, CA). Indirect
staining of the DIG-SCF gave better fluorescence signals than
direct staining methods using FITC-labeled sheep anti-DIG
antibodies (Boehringer Mannheim). Attempts to amplify the
FITC-labeled sheep anti-DIG signal using FITC-labeled rabbit
antisheep antibodies (Nordic Immunological Laboratories
B.V.; Tilburg, The Netherlands) resulted in high background.
Fluorescence signals of biotin-GF labeled cells were ampli-
fied by incubating the cells for 30 min on ice with biotiny-
lated antistreptavidin antibodies and fluorescently tagged
streptavidin, as described earlier [31]. For three-color analy-
sis, cells were stained in a final incubation step with fluo-
rescently tagged antibodies against CD34, CD71 or CD11b.
This was done by resuspending the cells in 50 µl HH with
FCS and azide containing 4% (vol/vol) normal rhesus serum
and 10% (vol/vol) normal mouse serum. After 15 min incu-
bation on ice, 50 µl of the respective antibodies diluted in HH
with FCS and azide were added, and the cells were incubated
for another 30 min. We used an anti-CD34 antibody (anti-
body 566, kindly provided by Dr. T. Egeland, Institute of
Transplantation Immunology, Rikshospitalet, Oslo, Norway)
that was labeled with FITC (Sigma) using standard proce-
dures. CD71-FITC and CD11b-PE mAbs were from Becton
Dickinson (Mountain View, CA).
To distinguish between living and dead cells, in some of
the experiments, propidium iodide ([PI], final concentration
0.6 µg/ml; Molecular Probes) was added prior to analysis to
samples that were stained with FITC and PE, or Hoechst
33258 ([H58], final concentration 1 µg/ml; Molecular Probes)
was added to samples that were also stained with TriColor.
Flow Cytometry
Samples were analyzed using a FACScan or a FACS
Vantage flow cytometer (Becton Dickinson; San Jose,
CA). Cells were illuminated with the 488-nm line of an
argon ion laser (Coherent Innova 90; Palo Alto, CA).
Green FITC fluorescence was measured through a 530-
nm/30-nm bandpass filter, orange PE fluorescence
through a 575-nm/26-nm or a 585-nm/42-nm bandpass
filter, and red TriColor or PI fluorescence was measured
through a 620-nm or a 650-nm longpass filter. H58 flu-
orescence was measured through a KV408 cut-off filter
using UV light (351/364 nm) from the second argon ion
laser (Series 2000, Spectra Physics; Mountain View,
CA) of the FACS Vantage. Data of 10,000-20,000 cells
per sample were stored in list mode using Lysys soft-
ware (Becton Dickinson) on an HP340 computer. Data
were analyzed using Spyro data analysis software devel-
oped by R.R. Jonker (TNO; Delft, The Netherlands) on
an Apple Macintosh computer. Viable H58- or PI-nega-
tive cells were analyzed in a light scatter window to
include cells with intermediate to high forward light
scatter and low to intermediate perpendicular light scat-
ter properties, and to exclude granulocytes, dead cells,
and cellular debris.
Statistics
Results are given as means ± standard deviation if appro-
priate. Standard deviations were calculated on the assumption
of a normal distribution.
RESULTS
Biological Activity and Cell Staining
SCF was labeled with DIG at molar DIG:protein (D:P)
ratios of 10:1, 50:1 or 100:1. The ability of these DIG-SCF
preparations to stimulate cell proliferation was assayed
using the human-factor-dependent megakaryocyte cell line,
MO7e [24, 25], which expresses 35,000-120,000 high-
affinity cell surface SCF receptors per cell [32, 33]. As
shown in Figure 1, SCF retained all of its biological activity
at a D:P ratio of 10:1. At D:P 50, approximately 67% of the
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biological activity of SCF remained, whereas at D:P 100
most of the biological activity was lost. All three prepara-
tions of DIG-SCF bound to MO7e cells, as was examined
by flow cytometry (Fig. 2). Binding of DIG-SCF was spe-
cific, since the fluorescence signal of cells incubated with
DIG-SCF in the presence of an excess of unlabeled SCF
was almost identical to that of control cells incubated with-
out DIG-SCF (Fig. 2). Despite the partial loss of biological
activity, the DIG-SCF sample prepared at a D:P ratio of 50
yielded a stronger fluorescence signal than the other samples.
This preparation was used in further experiments.
Correlation of Kit Expression and EPO-, IL-6-, and GM-CSF-R
Expression on BM Cells
The availability of DIG-SCF enabled us to examine
coexpression of Kit and receptors for other growth factors,
using biotinylated preparations of these growth factors. Cell
surface expression of Kit on low-density rhesus monkey BM
cells was studied in relation to the expression of EPO, IL-6-,
and GM-CSF-R, respectively, using DIG-labeled SCF in
combination with biotinylated preparations of each of these
GFs. In Figure 3, the results of one of five separate experi-
ments are shown. Staining with the labeled GFs was specific,
as demonstrated by incubation with DIG-SCF and biotin-GF
in the presence of a 100-fold molar excess of the relevant GF.
Combination of DIG-labeled SCF with biotinylated
EPO (Fig. 3B) showed that more than half of the Kit+ cells
also expressed the EPO-R. This Kit+/EPO-R+ fraction con-
tained approximately 11% of the low-density cells (Table 1)
and included cells with high, as well as cells with low or
intermediate, Kit expression. A subset of EPO-R+ cells did
not express Kit at detectable levels. This population repre-
sented approximately 6% of the BM cells and appeared to
be contiguous to the Kitlow/EPO-R+ subset. A separate
cluster of Kit+ cells did not express the EPO-R, and con-
tained ~9% of the low-density BM cells. Most of these cells
showed intermediate Kit expression.
Staining with DIG-SCF and biotin-IL-6 (Fig. 3C) indi-
cated that most cells with high Kit expression were IL-6-R–,
whereas most cells with high IL-6-R expression did not
express Kit. The Kit+/IL-6-R– subset contained approximately
10% of the low-density BM cells; the Kit–/IL-6-R+ fraction
represented ~22% of the cells (Table 1). A small population
containing approximately 7% of the cells expressed both
receptors, but mostly at intermediate levels.
Similar to the distribution of Kit and IL-6-R, analysis of
Kit and GM-CSF-R expression (Fig. 3D) showed a subset of
Kit+/GM-CSF-R– cells which comprised approximately
11% of the cells, as well as a cluster of Kit–/GM-CSF-R+
Figure 1. DIG-SCF was prepared at different D:P ratios. A con-
trol sample (D:P 0) was mock-labeled without adding DIG. MO7e
cells were incubated with serial dilutions of DIG-SCF for three
days in 96-well microtiter plates, after which a mixture of MTS
and phenazine methosulfate was added to the wells (see Materials
and Methods). The amount of 450 nm absorbance of each well
was measured, indicating the number of metabolically active
cells. Open circles represent mock-labeled control SCF; triangles,
squares, and closed circles represent DIG-SCF at D:P 10, 50, and
100, respectively. Each data point represents the mean value of
three different wells. Standard deviations are indicated. Dotted
horizontal line indicates 50% maximal stimulation of the cells.
Figure 2. Fluorescence his-
togram of Kit expression on
MO7e cells. MO7e cells were
sequentially stained with DIG-
SCF, anti-DIG mouse antibodies,
and PE-conjugated antimouse
goat antibodies (thick solid
lines). Control cells were incu-
bated in the presence of a 100-
fold molar excess of unlabeled
SCF (broken lines) or stained
only with anti-DIG mouse anti-
bodies and PE-conjugated anti-
mouse goat antibodies without DIG-SCF (thin solid lines). A) DIG-SCF labeled at a D:P ratio of 10:1; B) DIG-SCF labeled at a D:P
ratio of 50:1; C) DIG-SCF labeled at a D:P ratio of 100:1.
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cells which represented approximately 6% of the low-den-
sity cells (Table 1). Unlike Kit and IL-6-R, very few, if any,
cells expressing both Kit and GM-CSF-R were found.
Phenotypic Characterization of BM Subsets Based on Expression
of Kit and EPO-R
To examine the nature of the different subsets of GF-R-
expressing cells, phenotypic analysis of low-density rhesus
monkey BM cells was performed after triple-staining with
labeled GFs and mAbs against different cell-surface markers
(Figs. 4, 5, 6, and Table 2). Consistent with previous findings
[14], very few cells that expressed CD34 at high levels charac-
teristic for immature hemopoietic cells were EPO-R+ (Fig. 4A
and Table 2). Most of the CD34++ cells were Kit+/EPO-R– (Fig.
4A). The majority of the Kit+/EPO-R+ cells showed low CD34
expression, demonstrating that these cells were more differen-
tiated than the CD34++/Kit+/EPO-R– cells. The average level of
CD34 expression on the Kit–/EPO-R+ cells was even lower,
indicating that these cells were more mature than the Kit+/EPO-
R+ cells. Consistent with earlier results showing Kit+ as well as
Kit– cells within the CD34++ subset of rhesus monkey BM [17],
some CD34++ cells were also found in the Kit–/EPO-R– subset.
Almost all erythroid cells, identified by high CD71
expression [12, 13], were Kit+ (Fig. 4B) [17], and most of these
(~80%) expressed the EPO-R (Table 2). These CD71++ cells
comprised one-third of the cells in the Kit+/EPO-R– fraction
and the majority of cells in the Kit+/EPO-R+ fraction. Most of
the Kit–/EPO-R+ cells were CD71–. These CD71–/Kit–/EPO-
R+ cells displayed the low forward and perpendicular light
scatter pattern that is characteristic of normoblasts (not
shown), which are known to have lost CD71 expression [13].
The combined data are consistent with a model in which Kit
expression on erythroid progenitors precedes expression of
the transferrin receptor and the EPO-R. The data also demon-
strate that during terminal erythroid maturation, the EPO-R is
retained until a later differentiation stage than both Kit and
the transferrin receptor.
Analysis of expression of CD11b, which is a marker for
differentiating precursors of the granulocyte and monocyte lin-
eages, showed that most of these cells were Kit– and EPO-R–
(Fig. 4C and Table 2). This is consistent with the absence of
Table 1. Distribution of low-density rhesus monkey BM cells over
different fractions, based on expression of GF receptors
Fractiona %b
1 Kit+/EPO-R– 8.5 ± 1.9
2 Kit+/EPO-R+ 10.6 ± 5.3
3 Kit–/EPO-R+ 5.5 ± 2.5
4 Kit–/EPO-R– 49.8 ± 4.8
1 Kit+/IL-6-R– 10.2 ± 1.3
2 Kit+/IL-6-R+ 6.8 ± 0.4
3 Kit–/IL-6-R+ 22.2 ± 0.6
4 Kit–/IL-6-R– 38.7 ± 0.8
1 Kit+/GM-CSF-R– 18.4 ± 4.7
2 Kit+/GM-CSF-R+ NDc
3 Kit–/GM-CSF-R+ 11.3 ± 1.3
4 Kit–/GM-CSF-R– 41.7 ± 3.9
aCells were stained with DIG-SCF and biotinylated EPO, IL-6, or
GM-CSF.
bData represent the distribution of low-density BM cells over the recep-
tor-expressing regions as indicated in Figures 3B-3D (mean ± SD of
five separate samples), analyzed inside a light scatter window as
shown in Figure 3A. Note that percentages do not add up to 100%
since events outside the four receptor-expression windows were left
out of the analysis.
cND = not detectable.
Figure 3. Light scatter proper-
ties and GF-R expression of
low-density rhesus monkey BM
cells. A) Perpendicular versus
forward light scatter. The scat-
ter window that includes cells
with low to high forward and
low to intermediate perpendicu-
lar light scatter properties was
used to exclude granulocytes,
dead cells, and cellular debris.
B), C), and D) Coexpression of
Kit and receptors for EPO,
IL-6, or GM-CSF, respectively.
Cells were stained with DIG-
SCF combined with biotinylated
EPO, IL-6, or GM-CSF. The
windows used to analyze the
subsets coexpressing the differ-
ent GF-Rs are indicated. E), F), and G) Control cells were incubated in the presence of a 100-fold molar excess of the appropriate
unlabeled GF.
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Figure 4. Expression of CD34,
CD71, and CD11b on different
fractions of low-density rhesus
monkey BM cells, based on
expression of Kit and EPO-R.
Cells were stained with labeled
GFs and A) anti-CD34, B) anti-
CD71, or C) anti-CD11b mAbs,
and analyzed inside a light scatter
window as shown in Figure 3A, in
the regions that are indicated in
Figure 3B. From top to bottom are
shown: all cells; 1) Kit+/EPO-R–
cells; 2) Kit+/EPO-R+ cells; 3)
Kit–/EPO-R+ cells; and 4) Kit-
/EPO-R– cells. Dotted histograms
in the upper panels show back-
ground fluorescence of control
cells. Vertical broken lines indi-
cate the threshold values that were
used to discriminate between cells
with low or no fluorescence signal
and brightly stained cells. Results
are representative for three inde-
pendently performed experiments.
Figure 5. Expression of CD34,
CD71, and CD11b on different
fractions of low-density rhesus
monkey BM cells, based on
expression of Kit and IL-6-R.
Cells were incubated with DIG-
SCF combined with biotinylated
IL-6 and the same antibodies as in
Figure 4. Cells were analyzed
inside a light scatter window as
shown in Figure 3A in the regions
that are indicated in Figure 3C.
1) Kit+/IL-6-R– cells; 2) Kit+/IL-
6-R+ cells; 3) Kit–/IL-6-R+ cells;
4) Kit–/IL-6-R– cells.
Figure 6. Expression of CD34,
CD71, and CD11b on different
fractions of low-density rhesus
monkey BM cells, based on
expression of Kit and GM-CSF-R.
Cells were incubated with DIG-
SCF combined with biotinylated
GM-CSF and the same antibodies
as in Figure 4. Cells were analyzed
inside a light scatter window as
shown in Figure 3A, in the regions
that are indicated in Figure 3D. 1)
Kit+/GM-CSF-R– cells; 3) Kit+/GM-
CSF-R+ cells; 4) Kit–/GM-CSF-R–
cells (note that the Kit+/GM-CSF-
R+ fraction 2) contained too few
cells for analysis).
 by on December 13, 2006 www.StemCells.comDownloaded from 
281 Biotin- and DIG-Labeled Growth Factors
the EPO-R on myelomonocytic cells and the disappearance of
Kit during later stages of myeloid differentiation (see below).
Phenotypic Characterization of BM Subsets Based on Expression
of Kit and IL-6-R
In parallel with the examination of Kit and EPO-R
expression on hemopoietic subsets, we also studied coex-
pression of Kit with the IL-6-R and GM-CSF-R, respec-
tively. The immature cells were heterogeneous with respect
to IL-6-R expression, since high CD34 expression was
found on Kit+/IL-6-R+ as well as Kit+/IL-6-R– cells (Fig. 5A
and Table 2). Average CD34 expression was higher on
Kit+/IL-6-R+ than on Kit+/IL-6-R– cells, suggesting that on
average the Kit+/IL-6-R+ cells were more immature than the
Kit+/IL-6-R– cells.
Of the approximately 20%-25% of CD34++ cells that did
not express Kit, approximately two-thirds were IL-6-R+
(Fig. 5A and Table 2), which suggests that there are also
immature cells that express IL-6-R but not Kit. Almost all
CD11b+ cells were also found in the Kit–/IL-6-R+ subset
(Fig. 5C), which is consistent with the expression of IL-6-R
during differentiation of monocytes and granulocytes [15].
Therefore, the CD34++/Kit–/IL-6-R+ cells may represent dif-
ferentiating myelomonocytic progenitors that have lost Kit
expression. The CD11b– cells in the Kit–/IL-6-R+ population
probably represent mature T cells, which have been shown
to express IL-6-R at high levels [15, 34, 35].
Most of the Kit+ cells with low CD34 expression, which
include erythroid colony-forming cells (CFU-E) and
(pro)erythroblasts [17], were found in the IL-6-R– fraction
(Fig. 5A). Similarly, IL-6-R was not expressed on the
majority of the Kit+/CD71++ erythroid cells (Fig. 5B and
Table 2). However, the presence of approximately 14% of
the CD71++ cells in the Kit+/IL-6-R+ fraction indicated that
IL-6-R may be present on a subset of erythroid cells.
In conclusion, these results are consistent with a model in
which Kit and IL-6-R are coexpressed on a subset of progen-
itors which includes the most immature cells identified by
high CD34 levels. During maturation of erythroid cells, Kit
expression increases and IL-6-R expression decreases. In con-
trast, myeloid differentiation is accompanied by a decrease in
Kit expression and an increase in IL-6-R expression.
Phenotypic Characterization of BM Subsets Based on Expression
of Kit and GM-CSF-R
As shown in Figure 3, Kit+ and GM-CSF-R+ populations
showed little overlap. Kit+/GM-CSF-R– populations included
primitive cells with the highest CD34 expression and erythroid
cells with high CD71 expression (Figs. 6A and 6B). The
Kit–/GM-CSF-R+ population, on the other hand, contained
most of the CD11b+ cells (Fig. 6C and Table 2), which is con-
sistent with the expression of GM-CSF-R on monocytic
and granulocytic cells [16, 36]. As shown in Figure 6C, this
GM-CSF-R+ population covered a broad range of CD11b
Table 2. Distribution of low-density rhesus monkey BM cells over different fractions, based on expression of GF receptors and other cell surface markers
CD34++ CD71++ CD11b+
fractiona %b %b %b
1 Kit+/EPO-R– 8.7 (56.0) 2.5 (14.6) 0.2 (1.9)
2 Kit+/EPO-R+ 0.7 (4.2) 13.2 (78.9) 0.1 (1.0)
3 Kit–/EPO-R+ 0.2 (1.4) 0.3 (1.5) 0.4 (3.2)
4 Kit–/EPO-R– 2.5 (16.2) 0.4 (2.3) 6.0 (46.3)
1 Kit+/IL-6-R– 2.8 (20.7) 7.4 (58.9) 0.0 (0.2)
2 Kit+/IL-6-R+ 4.4 (33.4) 1.8 (14.1) 0.8 (4.7)
3 Kit–/IL-6-R+ 2.5 (18.8) 0.2 (1.4) 12.5 (75.2)
4 Kit–/IL-6-R– 1.2 (9.3) 0.5 (3.7) 0.2 (1.3)
1 Kit+/GM-CSF-R– 4.1 (53.3) 8.1 (66.7) 0.0 (0.6)
2 Kit+/GM-CSF-R+ NDc NDc NDc
3 Kit–/GM-CSF-R+ 0.4 (5.0) 0.1 (0.7) 6.3 (37.3)
4 Kit–/GM-CSF-R– 1.2 (16.5) 0.4 (3.4) 2.0 (11.8)
aCells were stained with labeled GFs and anti-CD34, anti-CD71 or anti-CD11b mAbs. Data represent results of one experiment, which was representative
of three independently performed experiments. Cells were analyzed inside a light scatter window as shown in Figure 3A, in the receptor-expressing regions
as indicated in Figures 3B-3D.
bData represent the percentages of BM cells that were found in the receptor-expression windows and that expressed CD34, CD71, or CD11b, respectively.
Between parentheses are the same data, relative to the total number of cells expressing these markers (normalized to 100%; note that percentages do not
add up to 100% since events outside the four receptor-expression windows were left out of the analysis). For example, 8.7% of the BM cells were
CD34++/Kit+/EPO-R–, which means that 56.0% of all CD34++ cells were found inside the Kit+/EPO-R– region.
cND = not detectable.
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expression, which indicates that GM-CSF-Rs are expressed
from immature (CD11blow) to mature (CD11bbright) mono-
myeloid cells. Additionally, some CD11b+/Kit– cells that did
not express detectable amounts of the GM-CSF-R were iden-
tified (Fig. 6C) which may represent a subset of natural killer
(NK) cells or their precursors. These combined results are con-
sistent with a model in which immature Kit+/CD11b– cells lose
Kit expression (and acquire GM-CSF-R) during monomyeloid
differentiation and develop into CD11b+ cells that express high
levels of GM-CSF-R.
DISCUSSION
In this paper, we show that DIG-SCF and biotinylated
GFs can be used to study coexpression of Kit and other
GF-Rs on hemopoietic cells. As expected from previous
studies using biotin [17], SCF could be labeled efficiently
with DIG, with retention of most of its ability to stimulate
cell proliferation. By combining DIG-SCF with biotiny-
lated GFs and mAbs against differentiation markers, we
were able to examine coexpression of Kit and receptors
for EPO, IL-6, and GM-CSF on rhesus monkey BM cells
at different stages of differentiation of various blood cell
lineages. This allowed a better definition of the subpopu-
lation structure of the immature hemopoietic cell compart-
ment. A schematic representation of changes in GF-R
expression during erythroid and monomyeloid differentiation
is shown in Figure 7.
The majority of the immature CD34++ hemopoietic
cells were Kit+. This is in agreement with previous studies
using anti-Kit antibodies on human cells [37-41] and
biotin-SCF on rhesus monkey BM cells [17]. In these
reports, using antibodies against CD34, CD33, CD38, and
HLA-DR, Kit expression was demonstrated on the most
immature subsets of CD34++ cells that can be detected in
vitro [42-44], which probably contain pluripotent hemo-
poietic stem cells relevant to hemopoietic reconstitution
[45]. In line with this, cells with long-term repopulating
ability were also found in the Kit+ fraction of murine BM
[19, 46-48].
GM-CSF-Rs were absent from or expressed at a very
low level on immature cells. This is in agreement with pre-
vious studies using purified CD34+ rhesus monkey BM
cells, showing no GM-CSF-Rs on erythroid and myeloid
progenitors with light scatter characteristics that were sim-
ilar to those we used for analysis [16]. Similar findings
were recently reported by McKinstry et al., who found lit-
tle or no binding of radiolabeled GM-CSF to purified
mouse BM subsets enriched for hemopoietic stem cells
[49]. Taken together, these results suggest that GM-CSF-Rs
are not expressed on hemopoietic stem cells, or only at
extremely low levels.
Within the population of CD34++/Kit+ immature hemo-
poietic cells, IL-6-R+ as well as IL-6-R- cells were found,
consistent with the previously demonstrated heterogeneity of
immature hemopoietic cells with respect to IL-6-R expression
[15]. The average CD34 expression of the CD34++/Kit+/IL-6-
R– cells is lower than that of the CD34++/Kit+/IL-6-R+ cells,
which might indicate that the IL-6-R+ cells are more imma-
ture. Previous three-color immunofluorescence experiments
showed that IL-6-Rs are expressed on a large subset of very
immature rhesus monkey or human cells with high CD34 and
low HLA-DR and CD38 expression [1, 45]. In situ autoradi-
ographic studies and reverse transcriptase polymerase chain
reaction also showed binding of IL-6 and expression of
mRNA for IL-6-R and its partner gp130 on highly enriched
fractions of murine BM stem cells and progenitor cells [49,
50]. However, as some cells with a very high CD34 expres-
sion are also present in the Kit+/IL-6-R– subset (Fig. 5), it is
possible that the most immature cells lack the IL-6-R. This is
supported by the finding that the majority of the long-term
culture-initiating cells and mixed colony-forming cells have
been found in the CD34+/IL-6-R– fractions of human BM and
cord blood [51]. This population did, however, express
gp130 and could respond to IL-6 in the presence of soluble
IL-6-R [51].
Maturation of progenitors into monomyeloid cells is
accompanied by a loss of Kit expression prior to acquisition
of the CD11b antigen (Figs. 4-6). The decline of Kit expres-
sion occurs after the progenitor cell stage, since cells that
form in vitro colonies (CFU-granulocyte/macrophage) were
previously shown to be CD34++/Kit+ [17]. Expression of the
Kit+
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IL-6-R ?
Kit+
EPO-R++
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IL-6-R ++
GM-CSF-R+
Kit+-
IL-6-R++
GM-CSF-R++
monocytes
stem cell
Kit
EPO-R
IL-6-R
GM-CSF-R
progenitors precursors mature blood cells
neutrophilic
granulocytes
erythrocytes
GM-CSF-R++
IL-6-R++
GM-CSF-R+++
IL-6-R+++
?
Figure 7. Schematic representation of erythroid and monomyeloid differen-
tiation, displaying receptor expression for SCF, EPO, IL-6, and GM-CSF.
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IL-6-R increases during monomyeloid differentiation, as
most CD11b+ cells were IL-6-R+, and high levels of IL-6-R
expression have been identified on monocytes, macro-
phages, and granulocytes, and on the precursors of these
cells (Fig. 5) [15, 49, 51-53]. As GM-CSF-Rs were present
on the majority of the CD11b+ cells but not on most of the
immature CD34++ cells (Fig. 6), expression of GM-CSF-R
also increased during differentiation into mature granulo-
cytes and monocytes. Similar results have been derived
from binding studies using 125I-GM-CSF or biotin-GM-
CSF on cell lines and murine and rhesus monkey BM cells
[16, 49, 54]. A small cluster of CD11b+ cells was found in
the Kit–/GM-CSF-R– fraction and may represent NK cells
[55]. CD11b– cells with the scatter pattern of lymphocytes
were found in the subsets that were Kit–, EPO-R– and GM-
CSF-R–. A fraction of these cells expressed IL-6-R (Fig. 5)
as is in agreement with the presence of IL-6-R on T lym-
phocytes and absence on resting B lymphocytes [15, 34, 35].
Differentiation into CD71++ erythroid cells is accompa-
nied by a gradual loss of CD34 expression of the immature
CD34++/Kit+ cells during the transition of BFU-Es, which are
CD34+ and express very high Kit levels, to CFU-Es, which
have been found in the CD34low/Kit+ fraction [17].
Simultaneously, EPO-R, which is not detectable on most
CD34++ cells, is upregulated during erythroid differentia-
tion, reaching maximal levels on CD71++/Kit+/EPO-R+
CFU-E and pro-erythroblasts [14, 56]. Expression of EPO-
R on a subset of cells that did not express Kit or CD71 and
showed the light scatter pattern characteristic of nor-
moblasts indicates that the EPO-R is retained on maturing
erythroid cells even after the loss of the transferrin receptor
and Kit. 
The expression of IL-6-R on erythroid cells is less
clear. Most of the CD71++ cells were IL-6-R–, which
demonstrated that IL-6-R is not expressed on the majority
of the erythroid cells. Moreover, most CFU-Es have been
found in the CD34+/IL-6-R- fraction of human BM and cord
blood [51]. A small subset of CD71++ cells was identified in
the Kit+/IL-6-R+ fraction, which may indicate that some
erythroid cells expressed IL-6-R. This would be in line with
the reported erythropoietic effect of IL-6, as demonstrated
by an increase in BM normoblasts induced by in vivo
administration of IL-6 in rats [57]. Alternatively, these cells
might also represent activated nonerythroid cells that are
Kit+/IL-6-R+, as CD71 is also upregulated on activated
cells of other lineages [12, 58].
In conclusion, GFs that are labeled with DIG provide a
useful extension of the existing cell-staining methods of
detecting receptor-expressing cells by flow cytometry. It is
relatively easy to construct biotin- or DIG-labeled GFs which
retain the ability to bind to receptor expressing cells. By
combining different labeled GFs with mAbs against cell-sur-
face markers, it is possible to distinguish small subpopula-
tions of BM cells which coexpress various high-affinity
GF-Rs simultaneously. This approach is particularly useful
to study changes in receptor expression patterns during dif-
ferentiation of immature hemopoietic cells and to explain
the stimulatory and inhibitory interactions of hemopoietic
GFs on phenotypically defined hemopoietic cells.
However, it is more difficult to exclude a direct action on a
given cell type, because the detection limit of the method is
approximately 50-100 receptor molecules per cell [15, 16,
31], whereas expression of only a few receptors can be suf-
ficient for a biological response [1, 16, 18]. It is likely that
neither radioactive labeling nor fluorochromes will yield
even lower detection levels, which means that detection of
such very low receptor levels can as yet only be achieved by
sensitive reverse transcriptase polymerase chain reaction
methods at the single-cell level.
Keeping these limitations in mind, simultaneous cell
staining with DIG-GF and biotin-GF can be used to identify
individual cells responding to multiple GFs. Since two
GF-Rs can engage in physical interactions when coex-
pressed on the same cell, as has recently been demonstrated
for Kit and EPO-R on transfected murine cell lines [59], the
ability to detect the binding of different GFs to the same
target cell can be used to examine whether similar interac-
tions can take place on primary hemopoietic cells. Moreover,
it provides an alternative approach to examination of the
sharing of receptor subunits among different GF-Rs on rare
hemopoietic cells, which are difficult to isolate in sufficient
numbers to perform competition experiments using radioac-
tively labeled GFs. A combination of various labeled GFs
with a panel of cell-surface markers will allow further char-
acterization of stem cells and progenitor cell subsets on the
basis of GF-R expression.
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